Merck proposes early licensing and manufacturing plan for monthly HIV PrEP pill
Merck announced early voluntary, royalty-free licensing and manufacturing plans to enable rapid access to alimatravir (MK-8527), an investigational once-monthly oral HIV-1 PrEP candidate, in low- and middle-income countries if approved. The company signed seven non-exclusive licenses with three sub-Saharan African manufacturers and four Indian firms to cover 129 LMICs, is supporting regional manufacturing in Africa and Latin America, and is investing in initial product manufacturing while Phase 3 EXPrESSIVE-10 and EXPrESSIVE-11 trials are under way. Phase 2 data in 350 participants showed similar adverse event rates to placebo and supportive pharmacokinetics, and Gates Foundation funding supports trial enrollment.
Merck granted royalty-free licenses for alimatravir covering 129 LMICs.
Context
Phase 3 trials of alimatravir are now enrolling in multiple countries. Merck signed early licenses and is investing in manufacturing. Regulators may review trial results and consider approval next.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked